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Should we continue population-based cervical cancer screening 
programme in Poland? A statement in favour
Andrzej Nowakowski1, 2, 3, Maryla Turkot1, Kinga Miłosz1
Organised cervical cancer screening programme in Poland introduced in 2006/2007 has never been optimal, largely 
due to low participation rate. However, recent analysis of trends in the burden of cervical cancer mortality revealed 
an acceleration of the downward trends in women of the screening age 25–59 around the time of the introduction 
of the programme. Possible factors responsible for this phenomenon include dissemination of Pap testing (mainly 
in opportunistic screening) and attempts to assure higher quality of screening procedures, which accompanied the 
roll-out of the screening programme. Despite the obvious flaws and limitations of the programme, its discontinu-
ation might result in adverse epidemiological, clinical and financial outcomes related to limiting the screening to the 
opportunistic mode only. Therefore the programme requires continuation and improvements. Unfavourable trends 
in the burden of the disease in older women require rising the upper age limit for screening to facilitate access to 
screening. Several strategies to raise participation need to be tested. The inevitable advent of more sensitive but 
less specific, molecular HPV screening requires pilot studies, evaluation of their outcomes and adjustments before 
full-scale introduction at the national level. According to European Guidelines, this may be executed only within an 
organised screening programme.
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Introduction 
Exfoliative cytology is the most common screening test 
for early detection of cervical cancer and its precursors in 
the developed countries around the world nowadays. It 
was developed by a Greek physician and scientist George 
Papanicolaou in the third decade of the 20th century [1]. 
A Romanian scientist Aurel Babes made a similar discovery 
at the same time, but it was the Papanicolaou method of 
cell staining which became the standard in cervical cytology 
around the world and the cervical cytology test (the Pap test) 
holds Papanicolaou’s name ever since. In 1925 a German 
gynaecologist Hans Hinselmann invented a colposcope — 
a device still in use in the gold standard procedure of triage 
of women with abnormal Pap test results. In the second half 
of the 20th century epidemiological observations started 
to indicate that cervical cancer might be caused by a sexu-
ally transmitted factor. Indeed, in 1983 Harald zur Hausen, 
a German virologist and his team isolated DNA of the human 
papillomavirus (HPV) from the tissue of cervical carcinoma 
[2]. A large body of scientific evidence gathered for the next 
decades confirmed the crucial role of genital HPV types 
in the pathogenesis of cervical carcinoma and Harald zur 
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Hausen was awarded the Noble Prize for his inventions in 
2008. In the 1990s Ian Frazer and Jian Zhou developed and 
patented a technology to produce HPV viral-like-particles, 
which induce humoral response and form the bases of HPV 
vaccines. The first of them was registered by FDA in 2006 
and three are currently in use around globe providing up 
to 70–95% protection against cervical cancer. In 2003 FDA 
approved the first commercial HPV test for clinical use in 
diagnosis of cervical cancer and three societies: American 
Cancer Society, American Society of Colposcopy and Cervi-
cal Pathology and American Society of Pathology published 
official recommendations on the use of HPV testing in ce-
rvical cancer screening [3]. 
Organised, population-based cervical cancer 
screening programmes — lessons learnt in other 
countries
Cervical cancer screening with the use of Pap testing 
enables detection of curable cervical cancer precursors 
and thus provides protection against the development of 
invasive disease. In most developed countries, Pap tests 
are performed in two different settings: as opportunistic 
screening and as population-based organised screening 
programmes. Opportunistic screening is based on collection 
of Pap smears when women visit gynaecological surgeries 
voluntarily for screening or during appointments for other 
reasons such as prenatal visits, contraception prescriptions 
etc. Population-based screening programmes are organised 
nationally or regionally and provide testing in accordance 
with an established policy which includes: invitations of 
women to screening, set age-ranges of the target popu-
lation and intervals between the tests and measures to 
ensure high quality of all parts of the programme. The main 
characteristics of both organised population-based and 
opportunistic cervical cancer screening modes are presen-
ted in Table I. Organised, population-based cervical cancer 
screening programmes seem to be more effective and have 
a higher impact on the reduction of the burden of cervical 
cancer [4]. Some of the Scandinavian countries implemen-
ted organised Pap-smear based screening programmes as 
early as in 1960s. Finland followed invitational screening in 
all municipalities. Denmark and Sweden had partially orga-
nised screening. Within 30 years after implementation, ce-
rvical cancer mortality in those countries decreased by 80%, 
66% and 52% respectively. On the other hand, in Norway 
which followed opportunistic way of screening until 1995, 
the observed decrease in mortality from cervical cancer 
was considerably less at the level of 40%. Another exam-
ple of high effectiveness of population-based organised 
screening is the United Kingdom. In the UK, opportunistic 
cytological screening was present since the 1960s, but an 
organised programme including a call/recall system and 
quality assurance started in 1988. Before 1988, mortality 
and incidence from cervical cancer decreased by 1–2% per 
year, whereas after 1988 the decrease accelerated to around 
7% annually. At the same time mortality rate from cervical 
cancer increased in the Republic of Ireland where there was 
no organised screening programme.
Recommendation of the Council of the European 
Union on cancer screening
Based on the success of implemented organised scre-
ening programmes and on the results of scientific studies, on 
December 2, 2003, the Council of the European Union issued 
Recommendation on cancer screening [5] for the Member 
States. In view of this document, organised screening pro-
grammes should be run for cervical, breast and colorectal 
cancers. Amongst the most important issues of the Recom-
mendation were: a) consideration of various (ethical, social, 
medical, organisational and economic) aspects before the 
programme commencement, b) programme cost-effecti-
veness, c) centralised data system and linkage with cancer 
registry, d) protection of personal data, e) quality assurance 
and evaluation, f ) adequate personnel training, g) equal 
access to screening. The Council Recommendation also 
invited the EU Commission to report on the implementation 
of cancer screening programmes, to encourage cooperation 
between the Member States in research and exchanging 
Table I. Selected major characteristics of organised population-based cervical cancer screening programmes and opportunistic screening 
Organised population-based cervical cancer screening programmes Opportunistic cervical cancer screening
 — Defined target population and age range
 — Defined and observed intervals between screening tests
 — Defined test
 — Invitations for screening
 — Database and IT system for collection and evaluation of screening data
 — Implemented algorithm for triage of women with positive screening 
tests
 — Quality evaluation and assurance of all steps and procedures in the 
programme
 — Studying the effects of the screening programme
 — Evaluation of the cost-effectiveness of screening
 — Avoiding of unnecessary testing outside the target population and 
intervals
 — Examination of women out of the target screening population e.g. 
20 years of age and younger
 — Incorrect intervals between examinations e.g. unnecessary testing 
every 6 months
 — Lack of implemented algorithm for triage of women with positive 
screening tests — unnecessary biopsies, conisations, complications 
and costs
 — Lack of quality evaluation and assurance of the screening procedures
 — Lack of follow-up of women with positive screening test results
 — Lack of evaluation of false-negative and false-positive screening tests 
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best practices. Finally, it recommended the development 
of new guidelines or updating of the existing guidelines 
for cancer screening.
European Guidelines for Quality Assurance in 
Cervical Cancer Screening
In 2008 a representative group of experts published 
the second edition of the European Guidelines for Quality 
Assurance in Cervical Cancer Screening [4]. This comprehen-
sive document encompassed all aspects of organisation of 
population-based cervical cancer screening programmes 
in the European Union and also touched on HPV vaccina-
tion, which was about to be introduced in Europe at that 
time. The guidelines stressed that cytological screening can 
prevent four out of five cases of cervical cancer, but only if 
the screening is provided in organised, population-based 
programmes with quality assurance at all levels.
The guidelines, similarly to EU Council recommenda-
tions, indicate that screening should be undertaken as a pu-
blic health intervention with identification and personal 
invitation of each woman in the eligible population. All 
the steps of the screening process as well as methods of 
quality assurance, monitoring and evaluation should be 
well defined by the programme policy and regulations at 
the regional and national level. At the time of publication 
the guidelines the screening test recommended by the 
experts was either conventional or liquid-based cytology 
performed every three to five years in case of normal re-
sults. The screening should start between the age of 20–30 
and continue to the age of 60–65. The opportunistic way 
of screening dependant on the initiative of the individual 
women or her doctor was discouraged by the guidelines. 
Such activities induce high coverage in selected parts of the 
population which are screened too frequently, coexisting 
with a low coverage in other population groups with less 
socioeconomic status, and heterogeneous quality, resulting 
in limited effectiveness and poor cost-effectiveness. The gu-
idelines also clearly indicate that new technologies should 
be tested within the organised screening mode and piloted 
before implementation.
The course of the organised cervical cancer 
screening in Poland and its potential impact on 
the epidemiology of cervical cancer
Organised cervical cancer screening programme in 
Poland was first initiated in 2006. From the beginning of 
2007, medical records of all procedures in the programme 
are recorded in the electronic database called SIMP (Polish: 
System Informatyczny Monitorowania Profilaktyki). Target 
age of women was set at 25–59 years and 3-year interval be-
tween normal tests was established. Between 2006 and 2015 
the programme was coordinated by a central and regional 
coordination centres, which mailed personal invitations for 
screening tests and were responsible for other aspects of 
the programme execution. The programme was partially 
concordant with the European Guidelines in terms of policy 
and organisation [6]. From the beginning of 2016, regional 
coordinating centres were shut down and the duties of the 
central coordination centre were limited to some aspects of 
quality assurance and audits. Mailing personal invitations 
was stopped and the programme became semi-opportuni-
stic. Low coverage ranging from 21% to 27% has been the 
major problem in the programme. At the same time high 
burden of opportunistic screening (possibly overscreening 
in certain cohorts) has been taking place [6]. Despite those 
obstacles, incidence of and mortality from cervical cancer 
have been decreasing with a possible acceleration of the do-
wnward trends around the 2006/2007 when organised scre-
ening was implemented. These positive trends are evident 
in the screening age cohorts (25–59 years). They might be 
potentially related to attempts to maintain/improve quality 
of the screening procedures and most probably to dissemi-
nation of Pap tests, performed mainly within opportunistic 
screening. According to questionnaire-based data from the 
Central Statistical Office in Poland, up 83% of women aged 
20–59 declare having undergone Pap testing in the recent 
3 years (Fig. 1) and this rate increased over a decade [7–9]. 
It is therefore possible that introduction of the organised 
programme and accompanying awareness campaigns re-
sulted in dissemination of Pap smears, majority of which is 
performed in opportunistic screening. Unfortunately, the 
downward incidence and mortality trends stopped in wo-
men 60+ years of age [10] and this requires prompt actions 
with focus on elderly women. Rising of the upper age limit 
of screening to at least 65 years of age should be promptly 
considered. 
The future of cervical cancer screening — human 
papillomavirus testing in organised programmes
Although Pap smear revolutionised secondary preven-
tion of cervical cancer, it is not a perfect screening test. 
Its evaluation is subjective and performer-dependant and 
sensitivity rarely exceeds 70–80% [4]. Recognition of the 
aetiological role of HPV in the development of cervical 
cancer and presence of the viral DNA in precancerous and 
cancerous cervical tissue enabled elaboration of diagnostic 
HPV tests, first of which was approved by the FDA in 2006 
for clinical use. Since then, numerous technologies aimed 
at detection of oncogenic HPVs have been marketed and 
in 2012 three influential societies in USA published joint 
recommendations on the use of HPV testing (co-testing 
with cytology) for primary screening of cervical cancer [3]. 
A substantial body of scientific evidence on the use of HPV 
testing in screening was collected over the next years and a 
supplement to European Guidelines for Quality Assurance in 
Cervical Cancer Screening was published in 2015 [11]. This 
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comprehensive document is largely dedicated to this new 
technology in cervical cancer screening. The main advanta-
ge of molecular HPV testing over cytology is its great sensiti-
vity approximating 99–100%. High negative predictive value 
of HPV tests enables extending intervals between screening 
rounds to 5 or even 10 years. However, lower specificity and 
positive predictive value of HPV testing especially in young 
(< 30 years of age) women carries a risk of increased rates 
of colposcopy referrals, biopsies, excisional diagnostic and 
therapeutic procedures resulting in overdiagnosis of regres-
sive lesions, overtreatment, adverse obstetrical outcomes 
and high costs. Also, algorithms for women with a positive 
HPV test have not been fully elucidated and adopted in 
clinical settings. Therefore HPV-based screening requires 
high level of organisation of the screening programme to 
avoid substantial increase in the number of women with po-
sitive test results and additional diagnostic and therapeutic 
procedures of no benefit to participating women [11]. HPV 
testing should not be offered in opportunistic screening. 
Many organisational, logistic, economic, clinical factors and 
considerations should be take into account before introduc-
tion of HPV-based screening [11]. Implementation of this 
service should be performed gradually, with pilot testing 
and evaluation before full-scale roll-out.
Why organised screening in Poland?
Although the course of the organised screening pro-
gramme in Poland, mainly due to low participation rate, 
has never been optimal, there are several arguments for 
continuation of the programme and its modification rather 
then discontinuation.
a) Recent analysis suggests that descending trends in the 
burden of cervical cancer accelerated after implemen-
tation of the screening programme [6].
Discontinuation of the programme might cause adverse 
epidemiological outcomes and rise in cervical cancer burden 
in the country. Access to screening cytology might become 
more difficult especially to women with lower socioecono-
mic status, who cannot afford private gynaecological care.
b) Actions are required to implement effective ways of 
rising participation in the screening programme.
Two years ago by the decision of the Ministry of Health, 
mailing of personal invitations to screening cytology (and 
mammography) was stopped. The arguments were high 
costs, lack of effectiveness, issues with access to personal 
identification data and consenting. There is a need to evalu-
ate different modes of rising participation in the programme 
(e.g. telephone and direct contacts with women by family 
midwives, mailing personal invitations) and implement the 
most effective strategy. Such initiatives may be fully evalu-
ated only within a setting of the organised screening.
c) Action is needed to reach high-risk older women with 
screening procedures.
Recent analysis indicates arrest of the decreasing trends 
in cervical cancer burden in women aged 60 years and above 
in Poland. Prompt action is required to elicit awareness of 
older women and facilitate access to screening procedures 
by raising the upper age limit of the programme to at least 
64 years.
d) Action is required to decrease potentially cost-ineffec-
tive opportunistic screening/overscreening.
Coverage of the organised programme is very low in 
certain cohorts, but statistical data indicated widespread 
participation in Pap testing at the same time (Fig. 1). A rele-
gation of the burden of screening procedures into the orga-
nised programme is therefore required. Certain measures to 
assure quality of the screening procedures are run within the 
programme and further are planned to evaluate and raise 
Figure 1. Questionaire-based data on participation in cervical cancer screening within the previous 3-years among Polish women [7] 
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screening quality. Data on these measures in opportunistic 
screening are unknown and more difficult to obtain.
e) HPV-based screening as a more effective strategy is 
being introduced in some countries in the world and 
Poland is inevitably facing its introduction in the ne-
arest future.
HPV-based screening should be piloted and evaluated 
before full-scale introduction. According to the Supple-
ments to European Guidelines for Quality Assurance in Ce-
rvical Cancer Screening published in 2015 pilot, evaluation, 
introduction and execution of HPV-based screening should 
be performed in organised screening programmes only.
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